Reactive oxygen species play an important role in both acute and chronic kidney diseases.
Chronic kidney disease is associated with various consequences to the cardiovascular …

Systemic arterial hypertension (SAH) is a chronic disease of multifactorial origin and one of
the main risk factors for major adverse cardiovascular events (MACE), which are the leading …

Renal artery stenosis (RAS) is a progressive disease and may lead to chronic kidney
disease by deterioration of renal functions. Endothelial dysfunction is an important causative …

β-blockers are among the most widely used drugs in the prevention and treatment of
cardiovascular disease, although they are associated with increased peripheral resistance …

Background Nebivolol represents a therapeutic class of beta blockers with high beta 1
selectivity and modulatory effect on vascular reactions by releasing nitric oxide (NO) from …

Nebivolol is a third generation beta-blocker, which can be distinguished from other beta-
blockers by its hemodynamic profile. It combines beta-adrenergic blocking activity with a …

Aims Nebivolol is a selective β1‐receptor antagonist with vasodilating properties. In patients
with essential hypertension, we tested the hypothesis that nebivolol increases systemic and …

Nebivolol is a vasodilating β-blocker, which can be distinguished from other β-blockers by its
haemodynamic profile. It combines β-adrenergic blocking activity with a vasodilating effect …

Hypertension is a major cardiovascular risk factor but most patients remain asymptomatic for
many years. Successful therapy not only needs to be effective, it also needs to be well …

Endothelial dysfunction is a systemic pathological state of the endothelium characterized by
a reduction in the bioavailability of vasodilators, essentially nitric oxide, leading to impaired …